About Arcus Biosciences Inc
Ticker
info
RCUS
Trading on
info
NYSE
ISIN
info
US03969F1093
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Terry J. Rosen Ph.D.
Headquarters
info
3928 Point Eden Way, Hayward, CA, United States, 94545
Employees
info
627
Website
info
arcusbio.com
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Metrics
BasicAdvanced
Market cap
info
$858M
P/E ratio
info
-
EPS
info
-$3.15
Dividend Yield
info
0.00%
Beta
info
1.54
Forward P/E ratio
info
0
EBIDTA
info
$-300M
Ex dividend date
info
-
Price & volume
Market cap
info
$858M
Average daily volume
info
1.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
3.33
Price to book
info
1.77
Earnings
EPS
info
-$3.15
EPS estimate (current quarter)
info
-$1.20
EPS estimate (next quarter)
info
-$1.10
EBITDA
info
$-300M
Revenues (TTM)
info
$258M
Revenues per share (TTM)
info
$2.86
Technicals
Beta
info
1.54
52-week High
info
$18.98
52-week Low
info
$6.50
50-day moving average
info
$9.30
200-day moving average
info
$14.10
Short ratio
info
8.71
Short %
info
14.39%
Management effectiveness
ROE (TTM)
info
59.77%
ROA (TTM)
info
17.26%
Profit margin
info
109.69%
Gross profit margin
info
$-190M
Operating margin
info
396.15%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
16.10%
Share stats
Outstanding Shares
info
106M
Float
info
65.8M
Insiders %
info
5.52%
Institutions %
info
83.69%
Analyst Insights & forecasts
info

85% Buy

15% Hold

0% Sell

Based on information from 13 analysts.

Average price target

info
$30.36
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.05
-$0.95
94.74%
Q1 • 24Beat
-$1.02
-$1.10
7.27%
Q2 • 24Beat
-$1.00
-$1.06
5.66%
Q3 • 24Beat
-$1.03
-$1.20
14.39%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$48M
$-92M
191.67%
Q3 • 24
$26M
$-94M
361.54%
Q4 • 24
45.83%
2.17%
88.63%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$1.25B
$687M
54.87%
Q3 • 24
$1.15B
$665M
57.83%
Q4 • 24
8.15%
3.20%
5.38%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$26M
$-29M
$48M
$25M
Q3 • 24
$-100M
$51M
$-2M
$-101M
Q4 • 24
484.62%
275.86%
104.17%
504.00%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcus Biosciences Inc share?
Collapse

Arcus Biosciences Inc shares are currently traded for undefined per share.

How many shares does Arcus Biosciences Inc have?
Collapse

Arcus Biosciences Inc currently has 106M shares.

Does Arcus Biosciences Inc pay dividends?
Collapse

No, Arcus Biosciences Inc doesn't pay dividends.

What is Arcus Biosciences Inc 52 week high?
Collapse

Arcus Biosciences Inc 52 week high is $18.98.

What is Arcus Biosciences Inc 52 week low?
Collapse

Arcus Biosciences Inc 52 week low is $6.50.

What is the 200-day moving average of Arcus Biosciences Inc?
Collapse

Arcus Biosciences Inc 200-day moving average is $14.10.

Who is Arcus Biosciences Inc CEO?
Collapse

The CEO of Arcus Biosciences Inc is Dr. Terry J. Rosen Ph.D..

How many employees Arcus Biosciences Inc has?
Collapse

Arcus Biosciences Inc has 627 employees.

What is the market cap of Arcus Biosciences Inc?
Collapse

The market cap of Arcus Biosciences Inc is $858M.

What is the P/E of Arcus Biosciences Inc?
Collapse

The current P/E of Arcus Biosciences Inc is null.

What is the EPS of Arcus Biosciences Inc?
Collapse

The EPS of Arcus Biosciences Inc is -$3.15.

What is the PEG Ratio of Arcus Biosciences Inc?
Collapse

The PEG Ratio of Arcus Biosciences Inc is null.

What do analysts say about Arcus Biosciences Inc?
Collapse

According to the analysts Arcus Biosciences Inc is considered a buy.